However, most AML blasts are refractory to the reprogramming process except for the MLL-AF9 fusion gene with a great variability between patients, suggesting that expression of MLL fusion is not sufficient to improve the efficiency of the reprogramming process. Here, KMT2A is linked to acute myeloid leukemia.